Skip to Main Content

The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis (ExTINGUISH)

Conditions

Diseases of the Nervous System

Phase IIB

What is the purpose of this trial?

Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.

  • Trial with
    National Institute of Neurological Disorders and Stroke (NINDS)
  • Start Date
    05/06/2022
  • End Date
    10/31/2025

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    05/18/2022
  • Study HIC
    #2000030521